Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.47 |
| ▸ | P4HB | P07237 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187214 | 0.94 | CYP4F2 (0.51) | CYP4F2CYP4A11P4HB | |
| SCHEMBL187126 | 0.92 | CYP4F2 (0.53) | CYP4F2CYP4A11P4HB | |
| SCHEMBL798217 | 0.86 | CYP4F2 (0.51) | CYP4F2CYP4A11P4HB | |
| SCHEMBL187215 | 0.84 | CYP4F2 (0.40) | CYP4F2CYP4A11 | |
| SCHEMBL798441 | 0.84 | CYP4F2 (0.60) | CYP4F2CYP4A11P4HB | |
| SCHEMBL798227 | 0.84 | CYP4F2 (0.60) | CYP4F2CYP4A11P4HB | |
| SCHEMBL798199 | 0.84 | CYP4F2 (0.60) | CYP4F2CYP4A11P4HB | |
| SCHEMBL797984 | 0.84 | CYP4F2 (0.60) | CYP4F2CYP4A11P4HB | |
| SCHEMBL187206 | 0.82 | TBXAS1 (0.37) | CYP4F2CYP4A11 | |
| SCHEMBL20816127 | 0.81 | CYP4F2 (0.47) | CYP4F2CYP4A11P4HB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1701931-B1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2018-10-10 | — | — | EP | claimed |
| US-20190084908-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2019-03-21 | — | — | US | disclosed |
| EP-1701931-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics, Inc. (US) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005068412-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084908-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | CYP4F2 2014/4885CYP4A11 87/4885P4HB 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.